Actimmune
(interferon gamma-1b)Phase 2Small molecule
Interferon gamma-1b is used to treat certain serious infections and a rare genetic disorder called chronic granulomatous disease, where the body's immune system doesn't work properly to fight off infections.[1] Actimmune is currently being investigated across 5 indications[3], with its most advanced program in Phase 2.[1]
Actimmune is one of 125 small molecule programs targeting Chronic Granulomatous Disease. It is currently in Phase 2.
5
Indications
30
Total Trials
2
Active Trials
124
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Idiopathic Pulmonary Fibrosis4 trials
Safety and Efficacy3 trials
Cystic Fibrosis2 trials
Children1 trial
Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000761·20 enrolled
19 more indications
Effectiveness1 trial
Unresectable1 trial
Hepatitis C1 trial
Immune1 trial
Bronchiolitis Obliterans1 trial
Cryptococcal Meningitis1 trial
Macular Edema1 trial
Osteopetrosis1 trial
ACTIMMUNE in Intermediate Osteopetrosis
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 2·NCT02666768·5 enrolled
Necrosis1 trial
A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001004·30 enrolled
Friedreich ataxia1 trial
Interferon Gamma-1b in Friedreich Ataxia (FRDA)
Completed·—·Phase 2·NCT01965327·12 enrolled
Sepsis1 trial
Acute Myeloid Leukemia1 trial
Regulatory
FDA Approval Timeline[4]
Feb 25, 1999
ACTIMMUNE
BLA BLA103836
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for interferon gamma-1b. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Interferon Gamma Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHorizon Therapeutics Ireland DAC